ORMP is leveraging its strong balance sheet - ~$142m in cash, equivalents, ST investments & deposits, no LT debt - to optimize its cash position. The company is augmenting its cash position with repayments / interest from collateralized loans issued to Scilex & to a domestic real estate project. Management expects its resources are sufficient to maintain planned activities for roughly at least the next year as clinical activities pick-up and as it maintains strategic share repurchases under its 2024 share buyback plan.
